Literature DB >> 3526499

A proposal for interpreting and reporting negative studies.

W W Hauck, S Anderson.   

Abstract

An issue of continuing interest is the interpretation and reporting of 'negative' studies, namely studies that do not find statistically significant differences. The most common approach is the design-power method which determines, irrespective of the observed difference, what differences the study could have been expected to detect. We propose an alternative approach, the application of equivalence testing methods, where we define equivalence to mean that the actual difference lies within some specified limits. This approach, in contrast to the design-power approach, provides a way of quantifying (with p-values) what was actually determined from the study instead of saying what the study may or may not have accomplished with some degree of certainty (power). For example, a possible outcome of the equivalence testing approach is the conclusion at the 5 per cent level that two means (or proportions) do not differ by more than some specified amount. The equivalence testing approach applies to any study design. We illustrate the method with a cancer clinical trial and an epidemiologic case-control study. In addition, for those studies in which one cannot specify limits a priori, we propose the use of equivalence curves to summarize and present the study results.

Entities:  

Mesh:

Year:  1986        PMID: 3526499     DOI: 10.1002/sim.4780050302

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  10 in total

1.  Establishing equivalence between scaled measures of quality of life.

Authors:  R Gonin; S Lloyd; D Cella; G Gray
Journal:  Qual Life Res       Date:  1996-02       Impact factor: 4.147

2.  Using statistical equivalence testing in clinical biofeedback research.

Authors:  J P Hatch
Journal:  Biofeedback Self Regul       Date:  1996-06

3.  Sample size determination for repeated measurements in bioequivalence test.

Authors:  K J Lui
Journal:  J Pharmacokinet Biopharm       Date:  1997-08

4.  Modeling and variable selection in epidemiologic analysis.

Authors:  S Greenland
Journal:  Am J Public Health       Date:  1989-03       Impact factor: 9.308

5.  Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. The German Hip Arthroplasty Trial (GHAT) Group.

Authors: 
Journal:  Arch Orthop Trauma Surg       Date:  1992       Impact factor: 3.067

6.  Publication bias and the pharmaceutical industry: the case of lamotrigine in bipolar disorder.

Authors:  S Nassir Ghaemi; Arshia A Shirzadi; Megan Filkowski
Journal:  Medscape J Med       Date:  2008-09-10

7.  Conditional equivalence testing: An alternative remedy for publication bias.

Authors:  Harlan Campbell; Paul Gustafson
Journal:  PLoS One       Date:  2018-04-13       Impact factor: 3.240

Review 8.  Spontaneous dog osteoarthritis - a One Medicine vision.

Authors:  Richard L Meeson; Rory J Todhunter; Gordon Blunn; George Nuki; Andrew A Pitsillides
Journal:  Nat Rev Rheumatol       Date:  2019-05       Impact factor: 20.543

9.  Clopidogrel pre-treatment in stable angina: for all patients > 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8.

Authors:  Petr Widimsky; Zuzana Motovská; Stanislav Simek; Petr Kala; Radek Pudil; Frantisek Holm; Robert Petr; Dana Bílková; Hana Skalická; Petr Kuchynka; Martin Poloczek; Roman Miklík; Marek Maly; Michael Aschermann
Journal:  Eur Heart J       Date:  2008-04-25       Impact factor: 29.983

10.  Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results.

Authors:  Muhammad Shahzeb Khan; Izza Shahid; Nava Asad; Stephen J Greene; Safi U Khan; Rami Doukky; Marco Metra; Stefan D Anker; Gerasimos S Filippatos; Gregg C Fonarow; Javed Butler
Journal:  ESC Heart Fail       Date:  2020-11-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.